Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Seladelpar (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors CymaBay Therapeutics
- 21 Dec 2021 An open-label extension phase has been added to the study. Number of treatment arms have been increased from 4 to 5 by the addition of Experimental: Seladelpar 50 mg (OLE phase).
- 21 Dec 2021 Status changed from completed to discontinued due to unexpected histological findings.
- 01 Jun 2021 Status changed from active, no longer recruiting to completed.